Measurement of NT-proBNP and copeptin may help identify those at high risk of heart failure (HF). However the value of NT-proBNP and copeptin has been little studied in the older population in primary care. This study aims to examine the use of NT-proBNP and copeptin in improving risk prediction and stratification of HF in older men with and without cardiovascular disease (CVD).
Introduction
Heart failure (HF) constitutes a major and increasing burden of morbidity and mortality in older people, leading to high healthcare costs. Identifying high risk individuals to target HF prevention in primary care remains a priority. Current guidelines have stimulated efforts to focus on identifying those with stage A (presence of risk factors) and stage B HF (asymptomatic ventricular dysfunction detectable on echocardiography), in order to implement early interventions to prevent progression to stage C (overt HF). 1 Although echocardiography provides effective non-invasive assessment of HF, routine echocardiographic screening is expensive and not currently recommended for use in the general population. 2 The optimal strategy for identifying people at high risk in the general population remains unclear, though the use of blood markers in primary care settings to identify those at high risk of developing HF is potentially promising. 3 The aetiology of HF involves interplay between myocardial ischaemia and remodelling, fibrosis, inflammation, and neurohormonal activation. 4 NT-proBNP, a peptide released from myocardium in response to ventricular wall stress and dysfunction, has emerged as a strong predictor of incident HF in high risk populations 5 and in the general population. 6 -12 In recent years, there has been interest in the neurohormones in the cascade of the arginine vasopressin (AVP) axis in the pathogenesis of HF. 4, 13 Plasma C-terminal provasopressin (copeptin), the C-terminal part of the AVP precursor peptide, is a vasoconstrictor that is secreted from the posterior pituitary in response to changes in plasma osmolarity and reduced cardiac output as part of a defence mechanism to preserve circulatory homeostasis. 4, 13 Copeptin has been established as a reliable marker of circulating AVP concentration in routine clinical practice. 4, 13 Higher levels of copeptin have been associated with increased risk of death in patients with HF, 13, 14 and copeptin has been shown to predict HF in patients with prior myocardial infarction (MI). 15 A recent report has highlighted the potential value of combined measurements of copeptin and NT-proBNP in elderly patients presenting in primary care with early symptoms of HF in predicting cardiovascular disease (CVD) mortality. 14 However, copeptin was not shown to predict HF in the general middle-aged population, 8 and the use of copeptin in predicting HF in the elderly, where most cases of HF occur, has not been established. While NT-proBNP has improved prediction of HF beyond established routine clinical risk factors 6 -8,10 -12 and the Health ABC Heart Failure Score, 12,16 the use of NT-proBNP testing in older adults (.60 years old) with and without CVD has been less studied, particularly in a primary care setting. We have therefore examined the clinical utility of NT-proBNP and copeptin in an elderly population of men with and without prevalent CVD. We assessed each biomarker's ability to improve the prediction of HF beyond established clinical HF risk factors (and Health ABC Heart Failure Score) and to what extent they add predictive information beyond inflammatory markers which have been shown to improve risk prediction for HF. 17 Finally, we assessed the performance of NT-proBNP and copeptin in improving risk stratification for incident HF.
Methods
The British Regional Heart Study is a prospective study involving 7735 men aged 40-59 years drawn from one general practice in each of 24 British towns, who were screened between 1978 and 1980. 18 The population studied was socio-economically representative of British men and comprises predominantly white Europeans (.99%). In 1998-2000, all surviving men, then aged 60-79 years, were invited for a 20th year follow-up examination, on which the current report is based. Ethical approval was obtained from all relevant local research ethics committees, and informed consent has been obtained from the subjects. All men completed a mailed questionnaire providing information on their lifestyle and medical history, had a physical examination, and provided a fasting blood sample. The samples were frozen and stored at -208C on the day of collection and transferred in batches for storage at -708C until analysis, carried out after no more than one freeze-thaw cycle. The 12-lead ECGs were recorded using a Siemens Sicard 460 instrument and were analysed using Minnesota Coding definitions at the University of Glasgow ECG core laboratory. 19 The men were asked whether a doctor had ever told them that they had angina or MI, HF, or stroke; details of their medications were recorded at the examination. 
Laboratory methods
Manufacturers' calibrators and controls were used in the measurement of NT-proBNP and copeptin in accordance with their instructions. NT-proBNP was determined using the Elecsys 2010 electrochemiluminescence method (Roche Diagnostics, Burgess Hill, UK). 24 The lower limit of sensitivity was 5 pg/mL. Low control coefficient of varaition (CV) was 6.7% and high control CV was 4.9%. Data on NT-proBNP were available in 3672 men. Copeptin was measured using an ultrasensitive method on a BRAHMS Kryptor compact plus (B.R.A.H.M.S, Bottisham, UK). The lower limit of sensitivity was 0.9 pmol/L. Low control CV was 4.7% and high control CV was 4.6%. Data on copeptin were available in 3560 men.
Follow-up
All men have been followed up from initial examination (1978) (1979) (1980) for cardiovascular morbidity, 25 and follow-up has been achieved for 99% of the cohort. In the present analyses, all-cause mortality and morbidity events are based on follow-up from re-screening in 1998 -2000 at mean age 60 -79 years to June 2010, a mean follow-up period of 11 years (range 10 -12 years). During this period, 1278 men had died. Survival times were censored at date of HF, death from any cause, or end of the study follow-up period (June 2010), whichever occurred first. Fatal coronary heart disease (CHD) events were defined as death with CHD [ International Classification of Diseases (ICD) 9th revision, codes 410 -414] as the underlying code. A non-fatal MI was diagnosed according to World Health Organization criteria. Evidence of non-fatal MI and HF was obtained by ad hoc reports from general practitioners supplemented by biennial reviews of the patients' practice records (including hospital and clinic correspondence) through to the end of the study period. Incident non-fatal HF was based on a confirmed doctor diagnosis of HF from primary care records and confirmed by a review of available clinical information from primary and secondary care records (including symptoms, signs, investigations, and treatment response) to ensure that the diagnosis was consistent with current recommendations on HF diagnosis. 26 The incidence and determinants of HF cases identified using this process have already been reported and are consistent with results from other studies. 22 Incident HF included incident non-fatal HF as well as death from HF (ICD 9th revision code 428).
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Statistical methods
The distribution of NT-proBNP and copeptin was skewed, and log transformation was used. Cox's proportional hazards model was used to assess the multivariate-adjusted hazards ratio (HR) (relative risk) in a comparison of quarters of NT-proBNP (copeptin) and for a 1 standard deviation increase in log NT-proBNP (log copeptin). In multivariate analyses, smoking [never, long-term ex-smokers (.15 years), recent ex-smokers (,15 years), and current smokers], social class (manual vs. non-manual), physical activity (four groups), alcohol intake (five groups), diabetes (yes/no), use of antihypertensive treatment (yes/no), pre-existing MI (yes/no), LVH (yes/no), and AF (yes/no) were fitted as categorical variables. Systolic blood pressure, FEV 1 , CRP, eGFR, and NT-proBNP were fitted as continuous variables. Receiver operating characteristic (ROC) curves and areas under the curve (AUC) (c-statistics) were used to assess the ability of NT-proBNP (copeptin) to predict HF beyond a score which included conventional routine risk factors as well as how NT-proBNP predicted beyond the Health ABC Heart Failure Score. Conventional routine risk factors included established risk factors for HF routinely obtained in clinical practice, e.g. age, obesity, hypertension, history of diabetes, history of MI, and history of angina. The Health ABC Heart Failure Score includes age, smoking, eGFR, heart rate, LVH, albumin, systolic blood pressure, history of MI and angina, fasting blood glucose, and antihypertensive treatment. 16 We calculated risk function estimates based on the regression coefficients of the Cox's models with and without NT-proBNP (copeptin) in the model. Tests for differences between the c-statistics for established risk function models with and without NT-proBNP (copeptin) were performed using an SAS macro (%ROC) with SAS software (version 9.3). To address the issue of how NT-proBNP evaluation may alter the risk stratification of men, all men were categorized according to three risk groups based on their 10 year predicted probabilities, ,10%, 10 -19%, and ≥20%, obtained from risk function models for HF events with and without NT-proBNP. The 20% cut-off was used as it is estimated that lifetime risk for developing HF is 20%. 27 We evaluated the ability of NT-proBNP to reclassify risk by calculating the net reclassification improvement (NRI) and the integrated discrimination improvement (IDI). 28 We also examined the prognostic value of NT-proBNP in healthy normal subjects, HF stage A subjects (those with traditional risk factors for CVD but without established CVD or HF), 1 and men with pre-existing established CVD (MI, stroke, or angina) based on a previous doctor diagnosis of one or more of these conditions. Stage A subjects included those with obesity, hypertension, cigarette smoking, dyslipidaemia (statin use), or diabetes1 (n ¼ 2411). Healthy normal included those with none of these risk factors and without pre-existing CVD (n ¼ 645).
Results Table 1 shows baseline characteristics of the study population. During the mean follow-up period of 11 years, there were 257 incident HF cases (5.9/1000 person-years) in the 3870 men with no previous diagnosed HF. Mean (geometric) NT-proBNP and copeptin were significantly higher in those with pre-existing CVD (MI, angina, or stroke) (186.8 vs. 81.5 pg/mL; P,0.0001 and 4.33 vs. 3.92 pmol/L; P ¼ 0.0006, respectively) than men without CVD. The 99th percentiles for NT-proBNP in those with and without CVD were 3254 and 1752 pg/mL and the corresponding 99th percentiles for copetin were 36.42 and 22.24 pmol/L, respectively. Figure 1 shows the Kaplan-Meier estimates of the cumulative incidence of HF by quarters of NT-proBNP and copeptin in all men. Risk of HF increased significantly with increasing quarters of NT-proBNP (log rank test P,0.0001) and to a weaker extent with increasing quarters of copeptin (log rank test P ¼ 0.002).
In all men, risk of HF increased significantly by NT-proBNP quarters after adjustment for age, smoking, physical activity, social class, alcohol intake, systolic blood pressure, prevalent diabetes, history of CHD (angina or MI), use of antihypertensive treatment, and LVH ( Table 2) . Further adjustment for eGFR, CRP, albumin, FEV 1 , heart rate, and ECG evidence of ischaemia and silent MI had minor effects on the findings. When examined separately in men with and without CVD, the strong positive association between NT-proBNP and HF was broadly comparable in both groups ( Table 2) . Exclusion of men who developed a non-fatal MI during the follow-up period made minor differences to the findings (data not shown). Raised Copeptin correlated significantly but only modestly with NT-proBNP (r ¼ 0.18; P,0.0001). Elevated copeptin was associated with increased risk of HF, but this was markedly attenuated after adjustment for conventional risk factors and was no longer significant after further adjustment for blood markers (model 2; Table 3 ). When stratified by presence of CVD, copeptin was only associated with risk of HF in those with CVD after adjustment for routine clinical risk. However, this association was also attenuated to borderline significance after adjustment for additional risk factors (model 2) and was completely abolished after further adjustment for NT-proBNP (1 SD increase in log copeptin HR 1.09, 95% CI 0.84-1.41; P ¼ 0.48). In contrast, the association between NT-proBNP remained highly significant after adjustment for copeptin (1 SD increase in log NT-proBNP HR 2.04, 95% CI 1.56-2.69; P,0.0001). CRP. NT-proBNP (but neither copeptin nor CRP) added significantly to HF prediction beyond either risk score. Adding NT-proBNP to a model which included conventional risk factors and CRP provided significant improvement in prediction (P≤0.0001). When examined separately by presence of CVD, NT-proBNP added significantly to HF prediction beyond conventional risk factors and the Health ABC Heart Failure Score in men both with and without CVD (P,0.0001) ( Table 4) . Neither copeptin nor CRP improved prediction beyond conventional risk factors in men with or without CVD (data not shown). A model in those with CVD which included conventional risk factors and NT-proBNP showed no improvement on addition of copeptin (c-statistic ¼ 0.721, 0.668-0.775 vs. 0.725, 0.673-0.776 without copeptin; evidence for improvement P ¼ 0.78).
We assessed the degree of reclassification occurring for HF prediction for a score based on established HF risk factors with NT-proBNP compared with a score based on established HF risk factors alone. The NRI in all men was estimated at 18.8% for NT-proBNP (P,0.0001). The NRI in non-events was -6.0% and the NRI in events was +24.8%. The IDI was also significant (0.076; P,0.0001). Similar NRIs were obtained if the Health ABC Heart Failure Score was used. We also examined the NRI separately in men with and without CVD. In men without CVD, the NRI was estimated at 27.4% (P,0.0001) (-5.5% and +32.9% in non-events and events, respectively) and for men with CVD the estimated NRI was 17.4% (P,0.0001) (+9.4% and +8.0% in non-events and events, respectively). IDIs of 0.082 and 0.062 were obtained for those with and without CVD, respectively (P,0.0001).
Discussion
In this study of older men, NT-proBNP markedly improved prediction of HF beyond the established Health ABC Heart Failure Score and beyond established routine clinical parameters, whereas copeptin and CRP did not. NT-proBNP improved sensitivity in the prediction of HF, and thus improved risk classification among those who experienced HF. Our finding extends those of previous studies by examining the prognostic value of NT-proBNP and improvement in risk prediction in those with and without CVD separately within the same general older population and comparing the predictive value of NT-proBNP with other markers including in particular copeptin, but also CRP. The findings that NT-proBNP improved prediction even in asymptomatic men suggests that it is detecting men with subclinical cardiac dysfunction (or capturing other risk pathways relevant to HF risk) in men not considered to be at elevated risk.
The association between NT-proBNP and HF is not explained by conventional risk factors for HF; symptoms of general poor health (lung function, renal dysfunction, and inflammation), heart rate, and presence of AF or evidence of ischaemia on ECG, and the association is not mediated by the development of an MI. NT-proBNP has been shown to be associated with the development of AF, 8 a strong risk factor for HF. We did not have information on AF during follow-up and it is possible that part of the association may be mediated by the development of AF. Although we did not have echocardiographic measures, previous studies have shown the association between NT-proBNP and HF to be independent of LV mass. Measurement of NT-proBNP is not currently recommended for CHD risk assessment in asymptomatic adults. 28 While several studies have evaluated the performance of NT-proBNP for the purpose of reclassifying HF risk in the general population, 628,10 -12 few have examined the performance of NT-proBNP separately in those without established CVD and in those with established CVD. Our study suggests that measurement of NT-proBNP improves risk prediction and stratification over models that consider clinical variables alone as well as the Health ABC Heart Failure Score in both asymptomatic men and men with established CVD. Of interest, work in part from our group suggests that NT-proBNP deserves greater consideration for general CVD risk screening. 24, 30 If this was to happen, concomitant screening for HF using NT-proBNP would be logical. Although measurement of NT-proBNP is currently expensive, it is likely that the assay cost will come down when NT-proBNP commercial patents expire and the assay is routinely available and used for general CVD risk screening.
In contrast, copeptin showed much weaker associations with HF than NT-proBNP in this older population and was not associated with increased HF risk in men with CVD after taking into account clinical risk factors and NT-proBNP. Although copeptin has been shown to be a potentially useful prognostic marker of mortality in addition to NT-proBNP and in addition to high-sensitivity troponin in HF patients, 14 ,31 copeptin was not a useful predictor of HF in this general older population without HF. This is consistent with a previous report showing no association between copeptin and HF in a middle-aged population. 10 The majority of men in this study (96.9%) had levels below the reference limit (97.5 percentile) of 16.8 pmol/L seen in a healthy population. 32 Thus copeptin does not appear to predict incident HF, but raised copeptin is a useful prognostic marker when HF is present and in those in whom the majority ( . 55%) were seen to have levels above this reference range. 31 Our study is not without some limitations. It was based on an older, predominantly white, male population of European origin, so that the results cannot be generalized directly to women, or to younger populations or other ethnic groups. The current findings are based on doctor-diagnosed HF, which is likely to underestimate the true incidence of HF in this study population. However, the other risk factor associations with HF risk in this report and in our previous report on obesity and HF 22 generally agree with previous data and therefore suggest potential external validity for our findings. Echocardiographic measurements were not carried out in the present study and we were not therefore able to differentiate systolic and diastolic HF. Like other studies, 628,10 -12 our reclassification model is not based on any current clinical guidelines, although it serves to illustrate the way in which NT-proBNP might usefully improve risk models as they develop.
In conclusion, we have shown that NT-proBNP but, importantly, not copeptin significantly improves prediction and risk stratification of HF beyond routine clinical parameters obtained in general practice settings in both older men with and without established CVD, suggesting potential for optimizing chronic HF therapy or to prevent its development. Further large studies are needed to determine the practicality and process as well as the potential cost-effectiveness of performing NT-proBNP testing in selected older adults in the general population to detect high risk subjects for HF. 
